

MODIFIED Discovery of Potent Protease Inhibitors for Covid-19 Treatment using Specifically Design Novel bis-amide Derivatives

Novel compounds have been developed for potent antiviral activity against SARS-CoV-2 by inhibiting the virus via a mechanism of action distinct from previous drug targets.

Researchers at Purdue University have developed a new class of noncovalent functionalized bis-amide inhibitors for treatment of Covid-19.

There remains an ongoing global health pandemic which has now affected over 170 million people to date and there is no available therapeutic option. The compounds developed by Purdue researchers in this disclosure are newer modified versions of bis-amide derivatives that have demonstrated potent inhibitory effect on SARS-CoV-2 enzyme, 3CLpro. These inhibitors have been evaluated in immunocytochemical and cellular assays against Covid-19 infections.

Advantages:

- Potent Covid-19 Antiviral Properties
- Improved Drug-Like Features

Potential Applications:

- Treatment of SARS-CoV-2
- Pharmaceutical Research and Development
- Pandemic Control

Technology Validation:

The bis-amide compounds potently inhibited SARS-CoV-2 in in vitro studies and immunocytochemistry assays.

Technology ID

2021-GHOS-69206

Category

Pharmaceuticals/Research Tools
& Assays

Authors

Arun K Ghosh
Andrew D Mesecar
Hiroaki Mitsuya

Further information

Joe Kasper
JKKasper@prf.org

Nathan Smith
nesmith@prf.org

View online



TRL: 3

Intellectual Property:

Provisional-Gov. Funding, 2020-12-01, United States | PCT-Gov. Funding, 2021-11-30, WO | NATL-Patent, 2023-05-31, United States

Keywords: bis-amide inhibitors, noncovalent functionalized, Covid-19 treatment, SARS-CoV-2, 3CLpro inhibitor, antiviral properties, drug-like features, pharmaceutical research, pandemic control, immunocytochemical assays